Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923158 | 0.88 | SCN9A (0.34) | HTR2CSLC6A4CNR2SPRKDM4C | |
| SCHEMBL27214597 | 0.87 | KDM4C (0.36) | ABL1PTGDR2KDM4C | |
| SCHEMBL27231322 | 0.87 | KDM4C (0.36) | ABL1PTGDR2KDM4C | |
| SCHEMBL27214539 | 0.87 | KDM4C (0.36) | KDM4C | |
| SCHEMBL29923235 | 0.87 | KDM4C (0.36) | KDM4C | |
| SCHEMBL29923128 | 0.86 | BRD4 (0.33) | HTR2CSLC6A4CNR2KDM4C | |
| SCHEMBL29923610 | 0.86 | BRD4 (0.33) | HTR2CSLC6A4CNR2KDM4C | |
| SCHEMBL29923104 | 0.85 | P2RX7 (0.35) | HTR2CSLC6A4CNR2PTGDR2KDM4C | |
| SCHEMBL29923604 | 0.85 | KCNH2 (0.34) | HTR2CSLC6A4CNR2SPRPDK2 | |
| SCHEMBL27231342 | 0.85 | P2RX7 (0.35) | HTR2CSLC6A4CNR2PTGDR2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | TAAR1, HTR1A, HTR1F | HTR2C 14/4885SLC6A4 95/4885CNR2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.